Literature DB >> 24628960

A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures.

Stefania Casu1, Annalisa Berzigotti, Juan G Abraldes, M Angels Baringo, Laura Rocabert, Virginia Hernández-Gea, Joan Carles García-Pagán, Jaume Bosch.   

Abstract

BACKGROUND: Understanding patients' attitudes to clinical experiences is essential for developing high-quality patient-centred healthcare, as a better knowledge of patients' tolerance and satisfaction might allow implementing measures that ameliorate comfort, care and use of resources. AIMS: We aimed to describe patients' tolerance and satisfaction to invasive hepatic haemodynamic procedures, and to investigate which factors might influence patients' perspective in this field.
METHODS: Visual Analogue Scale (VAS) questionnaires regarding pain and duration (for tolerance), and comfort and general handling (for satisfaction) were prospectively administered to all consecutive patients (N = 327) submitted to hepatic haemodynamic procedures (N = 355) in a tertiary care setting during 2011. VAS scores ranged between 0 and 100 mm and items were defined as excellent if <10 mm; good if 10-20 mm and inadequate if >20 mm. Clinical and laboratory data were also collected.
RESULTS: Satisfaction was excellent in >95% of cases (mean 2 ± 5 mm, median 0 mm) and average tolerance was good (15 ± 18 mm; median 6 mm). A percentage of 59% of patients had excellent tolerance, 9% good and 32% had inadequate tolerance. Duration and complexity of the procedure and limited operator's experience were associated with inadequate tolerance on univariate analysis; duration of the procedure remained the only independent factor associated with inadequate tolerance on multivariate analysis. Procedures lasting <35 min had a >80% probability of being well tolerated.
CONCLUSIONS: Satisfaction and tolerance to hepatic haemodynamic procedures are excellent and good respectively. Tolerance was decreased in long procedures; hence reducing as much as possible the duration of the procedures might further improve tolerance.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  HVPG; liver biopsy; patient-centred healthcare

Mesh:

Year:  2014        PMID: 24628960     DOI: 10.1111/liv.12522

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  3 in total

1.  Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection.

Authors:  Christian Jansen; Thomas Reiberger; Jia Huang; Hannah Eischeid; Robert Schierwagen; Mattias Mandorfer; Evrim Anadol; Philipp Schwabl; Carolynne Schwarze-Zander; Ute Warnecke-Eberz; Christian P Strassburg; Jürgen K Rockstroh; Markus Peck-Radosavljevic; Margarete Odenthal; Jonel Trebicka
Journal:  PLoS One       Date:  2015-02-03       Impact factor: 3.240

2.  Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy.

Authors:  Mattias Mandorfer; Karin Kozbial; Philipp Schwabl; David Chromy; Georg Semmler; Albert F Stättermayer; Matthias Pinter; Virginia Hernández-Gea; Monika Fritzer-Szekeres; Petra Steindl-Munda; Michael Trauner; Markus Peck-Radosavljevic; Juan C García-Pagán; Peter Ferenci; Thomas Reiberger
Journal:  Hepatology       Date:  2019-10-14       Impact factor: 17.425

3.  Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).

Authors:  Thomas Reiberger; Andreas Püspök; Maria Schoder; Franziska Baumann-Durchschein; Theresa Bucsics; Christian Datz; Werner Dolak; Arnulf Ferlitsch; Armin Finkenstedt; Ivo Graziadei; Stephanie Hametner; Franz Karnel; Elisabeth Krones; Andreas Maieron; Mattias Mandorfer; Markus Peck-Radosavljevic; Florian Rainer; Philipp Schwabl; Vanessa Stadlbauer; Rudolf Stauber; Herbert Tilg; Michael Trauner; Heinz Zoller; Rainer Schöfl; Peter Fickert
Journal:  Wien Klin Wochenschr       Date:  2017-10-23       Impact factor: 1.704

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.